Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
5(45%)
Results Posted
100%(2 trials)

Phase Distribution

Ph phase_1
5
45%
Ph phase_3
4
36%
Ph phase_4
2
18%

Phase Distribution

5

Early Stage

0

Mid Stage

6

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
5(45.5%)
Phase 3Large-scale testing
4(36.4%)
Phase 4Post-market surveillance
2(18.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

11

all time

Status Distribution
Active(8)
Completed(2)
Other(1)

Detailed Status

Active, not recruiting3
Not yet recruiting3
Completed2
Recruiting2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
5
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 15 (45.5%)
Phase 34 (36.4%)
Phase 42 (18.2%)

Trials by Status

active_not_recruiting327%
completed218%
recruiting218%
not_yet_recruiting327%
unknown19%

Recent Activity

Clinical Trials (11)

Showing 11 of 11 trials
NCT07428759Phase 1

Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years

Recruiting
NCT07284654Phase 3

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49

Active Not Recruiting
NCT07425392Phase 3

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination

Recruiting
NCT06049134Phase 4

Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy

Active Not Recruiting
NCT07406334Phase 1

A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months of Age Receiving a Single Booster Dose

Not Yet Recruiting
NCT07406347Phase 1

A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age

Not Yet Recruiting
NCT07105722Phase 1

A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age

Active Not Recruiting
NCT06986239Phase 1

Safety and Immunogenicity of PCV-LITE, a Low-dose of Pneumococcal Conjugate Vaccine With LiteVax Adjuvant

Not Yet Recruiting
NCT05879107Phase 3

Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults

Completed
NCT05425732Phase 3

Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)

Completed
NCT05767606Phase 4

Concomitant Administration of the Novavax Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Adults Aged ≥60 Years

Unknown

All 11 trials loaded

Drug Details

Intervention Type
COMBINATION PRODUCT
Total Trials
11